EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments

Andrew Dickerson, Jeannie S Huang, Laura E Bauman iD

JPGN Reports · 2024-11 · 5 (4) · 447-453

DOI: 10.1002/jpr3.12124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 05.09.2024. Verfasst von Andrew Dickerson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Gastroenterology University of California San Diego California USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Upadacitinib (UPA), a selective Janus kinase‐1 inhibitor, has demonstrated efficacy in inducing and maintaining remission in moderate to severe ulcerative colitis (UC) in adults. Current standard management for acute severe ulcerative colitis (ASUC) involves intravenous corticosteroids (IVCS) followed by infliximab (IFX) salvage therapy. Limited data exist on the utility of UPA in ASUC, particularly in adolescents. This case series reports the use of UPA as salvage therapy in hospitalized adolescents experiencing ASUC refractory to IFX.

Methods

We performed a retrospective chart review of hospitalized patients with ASUC who received UPA as salvage therapy after initiation of IVCS and failure of IFX.

Results

Three adolescents were hospitalized with ASUC for which IFX infusion treatments were unsuccessful. Initiation of UPA enabled patients to improve their Pediatric Ulcerative Colitis Activity Index scores to ≤35 and be discharged home. Hospitalization course, complications, and follow‐up information are provided.

Conclusion

UPA is a promising short‐term salvage therapy in adolescent ASUC cases resistant to conventional treatments. Prospective studies are warranted to elucidate its long‐term efficacy and safety in this specific population. These findings provide a novel therapeutic avenue for managing ASUC in adolescents, offering hope for those encountering treatment challenges.

Schlagwörter

Stichwörter der Autor:innen

Janus kinase inhibitorsacute severe colitiscolectomyinflammatory bowel disease

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Gastroenterology University of California San Diego California USA.
  • Rady Children's Hospital San Diego California USA.

ORCID-Profile: Laura E Bauman

Förderung

  • NIMHD NIH HHS

Zitieren

APA

Dickerson, A., Huang, J. S., & Bauman, L. E. (2024). Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Reports, 5(4), 447-453. https://doi.org/10.1002/jpr3.12124

Vancouver

Dickerson A, Huang JS, Bauman LE. Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments. JPGN Reports. 2024;5(4):447-453. doi:10.1002/jpr3.12124

BibTeX
@article{Dickerson2024,
  author = {Dickerson, Andrew and Huang, Jeannie S and Bauman, Laura E},
  title = {Upadacitinib as salvage therapy in adolescents with acute severe ulcerative colitis refractory to conventional treatments},
  journal = {JPGN Reports},
  year = {2024},
  volume = {5},
  number = {4},
  pages = {447--453},
  doi = {10.1002/jpr3.12124}
}
Kostenlos starten →